- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
We must protect drug innovation
January 5, 2009
Thank you for shining light [in your Dec. 15 editorial] on the negative effects of unrestrained litigation by generic medicine
marketers, aimed at breaking hard-won patents on branded prescription drugs.
MoreLilly eyes generic biotech drugs
January 5, 2009
Generic drugmakers have been the nemesis of companies like Eli Lilly and Co., but now the Indianapolis-based company and its
peers want to get in the generic game
themselves.
MoreLilly makes $6.5B acquisition
December 29, 2008
J.K. WallEli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim
Cornelius—and won.
MoreGeneric meds cost more than consumers realize
December 15, 2008
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
MoreLilly fighting with generic drug firms over Cymbalta, Alimta, 5 other medications
December 8, 2008
J.K. WallEli Lilly & Co. has filed lawsuits against seven generic drug companies in federal court in Indianapolis, asking a judge to
declare its Cymbalta patent valid and to tell the generic companies to back off.
MoreEli Lilly investing $100M in China, hoping to attract research partners
December 1, 2008
Brian SpegeleHoping to increase sales in China's rapidly growing pharmaceutical market, Eli Lilly and Co. is charging ahead
with
plans to invest $100 million in venture capital in the region over the next several years.
MoreLilly buys ImClone as part of strategy to capitalize on cancer-drug market
October 13, 2008
J.K. WallEli Lilly and Co. has written a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. Cancer drugs are now the best-selling class of drugs in the world and one of the fastest growing.
Lilly taps hedge fund to cut research costs for Alzheimer's drugs
August 11, 2008
J.K. WallEli Lilly and Co.'s unorthodox efforts to develop new treatments for Alzheimer's disease--if successful--could usher in a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs of two experimental compounds to treat Alzheimer's disease.
Lilly expects FDA approval of long-acting version of Zyprexa
February 4, 2008
J.K. WallEli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the
antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S.
Food and Drug Administration on Feb. 6.
MoreLilly's plan to outsource more work is good news, bad news
December 17, 2007
J.K. WallEli Lilly and Co. will shrink itself with "great intensity" over the next few years, in part by
outsourcing. For other local life sciences firms, that's a fat pitch for new business. But it's not clear if non-Lilly firms
can grow fast enough to offset the jobs and wages Indianapolis will lose from Lilly.
MoreLilly under gun to replace aging blockbuster Zyprexa
November 5, 2007
J.K. WallThere's a $2 billion hole in Eli Lilly and Co.'s future. That's roughly how much pretax profit Lilly derives each year from
its best-seller, Zyprexa, according to calculations by IBJ. And it's how much black ink will start running off Lilly's books
once Zyprexa's U.S. and European patents expire in 2011.
MorePrescription drug abuse on the rise
August 13, 2007
J.K. WallWhen the Department of Justice slapped St. Vincent Indianapolis Hospital with a $1.2 million fine last month, it stunned local
medical professionals. But the issue behind St. Vincent's troubles is no surprise. The diversion of prescriptions drugs from
the medical field into recreational use is a widespread problem in Indiana and the nation.
MoreLilly still breathing in inhaler pursuit
April 2, 2007
J.K. WallPfizer Inc.'s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open
for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer's troubles might cause
doctors and patients to sour on all inhaled insulin products.
MoreAriad patent victory over Lilly among largest in 2006
January 3, 2007
Eli Lilly and Co.’s loss in May of a patent-infringement lawsuit brought by Ariad Pharmaceuticals
Inc. went down as the 6th-largest such jury award last year, a Bloomberg analysis shows.
MoreComplaints accuse Lilly of illegally marketing Zyprexa
December 11, 2006
Tom MurphyEli Lilly and Co. is facing another round of litigation over its star seller, Zyprexa, as insurers and third-party payers
ask to be reimbursed for covering the antipsychotic drug.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.